Fenwick Represents Loxo Oncology in $260.8 Million Follow-On Offering

June 21, 2017

​​Fenwick & West represented Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, in its $260.8 million follow-on offering of common stock. Loxo Oncology sold 3,622,500 shares of common stock including 472,500 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock, at a public offering price of $72.00 per share. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.

​​Morgan Stanley, Cowen, and Citigroup acted as the joint book-running managers for the offering. Stifel and BTIG acted as joint lead managers.

​​The Fenwick transaction team included corporate lawyers Robert Freedman, Effie Toshav, Julia Forbess, Jordan Roberts and Can Sun.​​​